All News

burnout work overworked

ICYMI: Rheumatologists Rank 2nd in Physician Burnout

d Jack Cush, MD

The 2021 Medscape Survey on Physician burnout ranks rheumatology second, just behind Critical Care medicine.

The survey included over 12,000 physcians from 20 specialties. While 42% of MDs claimed to be burnt-out, Rheumatologists claimed this 50% of the time. The top 3 this year were Critical care (51%), Rheumatology (50%) and infectious disease (49%).

Read Article
Lungs ILD

ICYMI: Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease

d Jack Cush, MD

Genentech announced Thursday that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adul

Read Article
FDA-Building_1.png

ICYMI: Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA

d Jack Cush, MD

The FDA has notified healthcare professionals of a safety alert concerning tofacitinib (Xeljanz), noting that preliminary results from a long-term safety clinical trial show an increased risk of serious heart-related problems and cancer with tofacitinib (compared to adalimumab) when given to at-risk rheumatoid arthritis patients. These findings are in addition to the thrombotic risks (added to the label), potential risks including blood clots in the lungs and death.

Read Article
patient.safety.jpg

ICYMI: JAK Inhibitor Misses Endpoint in Safety Study. Now What?

d MedPage Today

Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.

Read Article
RheumNow Podcast square

RheumNow Podcast – As Good As I Ever Was (7.2.2021)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
VEXAS is a new somatic mutation disorder with overlap with relapsing polychondritis. Thus older makes with ear/nose defects, MCV >100, Plt<200 could have the VEXAS-RP overlap @RWCSmtg https://t.co/Pqh6rYD96C
Dr. John Cush RheumNow ( View Tweet)
ProDERM Study: IVIG in Dermatomyositis--The ProDERM study show that IVIg is safe, effective and superior to placebo in patients with dermatomyositis (DM). https://t.co/HOB8CYn9yc https://t.co/4nNRRhzHVO

Links:

Dr. John Cush RheumNow ( View Tweet)
Is Q-DAPSA the answer to disease activity scoring in PsA? Dr. Rachel Tate ( @uptotate) provides some insight. https://t.co/fbi3Kbd2GS https://t.co/vBhWsbQYlg

Links:

Dr. John Cush RheumNow ( View Tweet)
"Arthritis Mutilans" - worse outcome to chronic inflammatory arthritis is due to 5 disorders: 1) RA 2) Psoriatic arthritis 3) Tophaceous gout 4) polyarticular JIA 5) Multicentric reticulohistiocytosis (Ive never seen this!!) https://t.co/XYmBEW1F0R https://t.co/010QYkOO7E

Links:

Dr. John Cush RheumNow ( View Tweet)
Serious problem! Pulmonologists believe that MTX causes and/or worsens ILD. MTX causes hypersensitivity pneumonitis, not ILD. RA, lupus DM, PSS cause ILD and they may need MTX to manage their disease. Do your own research, look at this paper to start. https://t.co/vUyCxJP2Mh

Links:

Dr. John Cush RheumNow ( View Tweet)

Protective Effects of Colchicine in Non-Hospitalized COVID-19 A press release from the Montreal Heart Institute has announced that the COLCORONA clinical trial has provided evidence of the protective effect of colchicine. Read more: https://t.co/xW5SchMUeK https://t.co/tUoDTJKbVG

Links:

Dr. John Cush RheumNow ( View Tweet)
Psoriasis has greatest risk of MTX liver dz - a Danish Population study of PsO, PsA & RA pts taking MTX. Risk of liver Dz was most in PsO, followed by PsA, then RA. PsO had 1.6-3.4 fold risk (mild-severe) liver dz (vs RA). PsA was 1.3-1.6x higher) https://t.co/pAo9KFr5fO

Links:

Dr. John Cush RheumNow ( View Tweet)

1/3 of patients with rheumatoid arthritis had unacceptably high levels of pain 5 years after diagnosis, often despite low levels of inflammation, Swedish researchers found. Read more: https://t.co/K8zf1pE9jM https://t.co/eu2Byo6dx4

Links:

Dr. John Cush RheumNow ( View Tweet)
The ACR has a new position on patient safety and site of service for biologics— it strongly believes infusions should be given in a monitored health care setting with onsite supervision by a provider w/ training in biologic infusions. https://t.co/NONozoIIq6 https://t.co/PQMvUZqnMW

Links:

Dr. John Cush RheumNow ( View Tweet)
A study of rheumatologists in Ontario, Canada has shown an increasing percentage of women in rheumatology; unfortunately they have lower salaries but see fewer patients than do their older, male colleagues. Read more: https://t.co/JM0345p8f1 https://t.co/y95LQ6lX5i

Links:

Dr. John Cush RheumNow ( View Tweet)
Download this week’s podcast titled “Good as I Ever Was”. You can find us on SoundCloud and wherever you download your podcasts. https://t.co/hVMf8X5Dx3 https://t.co/uUDCXzO2eU

Links:

Dr. John Cush RheumNow ( View Tweet)
New ACR Rheumatoid Arthritis Guideline: Emphasis on Methotrexate https://t.co/J9wmcZr17D

Links:

Dr. John Cush RheumNow ( View Tweet)

How risky are family gatherings, birthday parties and informal social gatherings? Read more… https://t.co/jyGHakndUt https://t.co/7eps0EFVWy

Links:

Dr. John Cush RheumNow ( View Tweet)
Brand new RheumNow podcast up titled “As Good As I Ever Was” Download now. https://t.co/hVMf8X5Dx3 https://t.co/2R2kq7dwp5 https://t.co/5mahn4D46M

Links:

Dr. John Cush RheumNow ( View Tweet)
Therapeutic Drug Monitoring for Infliximab: Might it Actually Work? https://t.co/Onl6cijKbb https://t.co/jnwx4ZZvhz

Links:

Dr. John Cush RheumNow ( View Tweet)
×